share_log

藥明巨諾-B：截至2023年12月31日止年度之年度業績公告及上市所得款項淨額用途變更

JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING

HKEX ·  Mar 20, 2024 01:34

Summary by Moomoo AI

藥明巨諾-B（JW Therapeutics）公佈截至2023年12月31日止年度業績，收入達人民幣173.9百萬元，較上年增加19.3%。毛利增加50.1%至人民幣88.2百萬元，毛利率提升至50.7%。年內虧損減少至人民幣768.0百萬元。公司繼續推動其靶向CD19自體CAR-T細胞免疫治療產品倍諾達®的商業化，並預期銷售收入將持續增加。研發開支輕微增加至人民幣413.6百萬元。公司亦宣佈將未動用的上市所得款項淨額重新分配至研發活動及技術平台開發，以支持業務增長。董事會不建議派發2023年末期股息。
藥明巨諾-B（JW Therapeutics）公佈截至2023年12月31日止年度業績，收入達人民幣173.9百萬元，較上年增加19.3%。毛利增加50.1%至人民幣88.2百萬元，毛利率提升至50.7%。年內虧損減少至人民幣768.0百萬元。公司繼續推動其靶向CD19自體CAR-T細胞免疫治療產品倍諾達®的商業化，並預期銷售收入將持續增加。研發開支輕微增加至人民幣413.6百萬元。公司亦宣佈將未動用的上市所得款項淨額重新分配至研發活動及技術平台開發，以支持業務增長。董事會不建議派發2023年末期股息。
JW Therapeutics announced its results for the year ended 31 December 2023 with revenues of RMB173.9 million, an increase of 19.3% year-on-year. Gross profit increased 50.1% to RMB88.2 million and gross margin increased to 50.7%. Loss for the year decreased to RMB 768.0 million. The Company continues to drive the commercialization of its targeted CD19 autologous CAR-T cell immunotherapy product Benoda® and expects continued sales revenue growth. R&D expenditure increased slightly to RMB413.6 million. THE COMPANY ALSO ANNOUNCED THE REDISTRIBUTION OF NET UNUSED LISTING PROCEEDS TO R&D ACTIVITIES AND TECHNICAL PLATFORM DEVELOPMENT TO SUPPORT BUSINESS GROWTH. The Board of Directors does not propose a final dividend for 2023.
JW Therapeutics announced its results for the year ended 31 December 2023 with revenues of RMB173.9 million, an increase of 19.3% year-on-year. Gross profit increased 50.1% to RMB88.2 million and gross margin increased to 50.7%. Loss for the year decreased to RMB 768.0 million. The Company continues to drive the commercialization of its targeted CD19 autologous CAR-T cell immunotherapy product Benoda® and expects continued sales revenue growth. R&D expenditure increased slightly to RMB413.6 million. THE COMPANY ALSO ANNOUNCED THE REDISTRIBUTION OF NET UNUSED LISTING PROCEEDS TO R&D ACTIVITIES AND TECHNICAL PLATFORM DEVELOPMENT TO SUPPORT BUSINESS GROWTH. The Board of Directors does not propose a final dividend for 2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated